International Institute of Cancer Immunology, Inc.;Sumitomo Dainippon Pharma Co., Ltd.
发明人:
申请号：
EP14775899.9
公开号：
EP2982681A1
申请日:
2014.03.28
申请国别(地区):
EP
年份:
2016
代理人:
摘要：
The present invention provides a compound represented by the formula (1):wherein Xa and Ya are each a single bond and the like,cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7 - 30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2):wherein Xb and Yb are each a single bond and the like,cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7 - 30 amino acid residues, or cancer antigen peptide C, andcancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7 - 30 amino acid residues containing one cysteine residue,or a salt thereof, and the like.
